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INTRODUCTION
Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Traditional therapies focus on alleviating manifestations secondary to CFTR dysfunction. A new oral treatment (ivacaftor , Vertex Pharmaceuticals, Boston, Massachusetts) has been licenced specifically for those with the G551D-CFTR mutation. Ivacaftor, a CFTR "potentiator", increases the open time of activated CFTR at the cell surface, restoring chloride-transport activity of the G551D-CFTR protein 1 .
To date, sustained improvements in quality of life, incidence of pulmonary exacerbations, respiratory symptoms, pulmonary function, weight, and biomarkers of CFTR activity (sweat chloride and nasal potential difference) have been reported following treatment with ivacaftor in patients that are heterozygous for the G551D mutation with mildto-moderately impaired lung function, without substantial adverse effects 2, 3, 4, 5 . More recently, administration of ivacaftor has also revealed clinical improvements in severely ill patients 6 and a G551D homozygote 7 .
Although common clinical assessments such as spirometry and body weight provide key endpoints for the evaluation of new CF treatments, their sensitivity to detect change in early disease has been questioned 8 . Furthermore, measurements of lung function cannot accurately predict patients' exercise capacity. Aerobic fitness (maximal oxygen uptake, V̇O 2max ) is of particular clinical importance in patients with CF given its association with longevity 9,10 , quality of life 11 and reduced risk of hospitalization 12 . However, exercise testing as an outcome in both physical therapy practice and therapeutic trials remains in its infancy 13 .
Understanding how the clinical alterations evident following pharmacological or physical therapy treatment translate to patients' physical function is important.
Only 1 previous study investigating the effects of ivacaftor has incorporated an exercise testing measure 7 , documenting a 292% (+410 m) improvement from baseline in the distance achieved during the 6-minute walk test in a female adult (G551D homozygote) following 12 months of treatment. Although tests such as this are common practice within physical therapy for individuals with CF, a number of methodological issues accompany these crude tests, which must be considered when used in this context. First, these tests are often subjective and submaximal in nature and fail to quantify physiologically a maximal effort. Second, the derived parameters are limited to heart rate and arterial oxygen saturation, which are often not presented and do not provide physiological data to support the mechanism(s) responsible for any observed change.
Maximal cardiopulmonary exercise testing (CPET), incorporating measurement of gas exchange, provides the most precise measurement of aerobic fitness. Much of the value of CPET resides in its capacity to describe the integrated function of the pulmonary, cardiovascular and muscular systems during exercise. Moreover, in addition to V̇O 2max , additional key parameters of aerobic exercise function can also be obtained, such as the O 2 cost of exercise (exercise efficiency) 14 . In response to the European CF Society (ECFS) Clinical Trials Network Standardization Committee's call to assess the validity, reproducibility and feasibility of outcome measures to be used in CF, a valid protocol for use with young patients with CF was recently presented 15 . Furthermore, the typical error associated with the derived outcome measures has since been presented 16 , enabling meaningful change from therapeutic or physical therapy interventions to now be ascertained.
However, to our knowledge there are no reports of effect of ivacaftor on patients' aerobic fitness assessed using the reference standard CPET.
The purpose of this report was to provide novel data from CPET in 2 teenage patients with cystic fibrosis (∆F508/G551D) treated with ivacaftor to demonstrate (1) the effects of ivacaftor on aerobic function and (2) the possible factor(s) modulating this response. By answering these questions, the report will provide novel data on the utility and feasibility of CPET as a clinical outcome measure. flucloxacillin (500 mg twice daily).
CASE DESCRIPTION Participants

Description of Intervention
The main goal of this intervention was to assess the influence of orally administered ivacaftor treatment (150 mg 12 hourly) on CPET-derived measures of aerobic function in 2 young patients with CF in conjunction with common clinical outcome measures. To monitor the effects of treatment, the 2 teenage patients, both compound heterozygotes (G551D/ΔF508), underwent routine clinical assessments for a 20-week duration.
In addition to this, CPET was performed before and after (6 and 12 weeks) initiating orally administered ivacaftor treatment to assess whether any change in aerobic function was evident and, if so, the physiological factor(s) responsible for this. These time points for reassessment were implemented to enable comparison of intervention-induced changes with the typical error of the CPET measurements established in this patient population over this time period to identify clinically meaningful changes 16 . The patients continued their normal maintenance medications as required and continued with their typical physical activity and nutritional intake patterns. Additional measurements of central (O 2 delivery) and peripheral (O 2 extraction/ utilization) factors that can influence V̇O 2max were also obtained to understand the mechanism(s) responsible for any change.
Maximal Cardiopulmonary Exercise Testing.
Participants were instructed to arrive at the exercise laboratory in a rested state, 2 hours or more postprandial and having refrained from caffeine for 2 hours or more. predicted reference data. [17] Pulmonary gas analysis. Prior to each exercise test, a metabolic cart (Metalyzer 3B Cortex, Biophysik, Leipzig, Germany) was calibrated using gases of known concentration, and the turbine volume transducer using a 3 L calibration syringe (Hans Rudolph, Kansas City, MO).
Breath-by-breath pulmonary gas exchange and ventilation were measured and averaged to 15-second time bins. The highest 15-second stationary average V̇O 2 from the combined ramp and supramaximal exercise tests (described later) was taken to represent V̇O 2max , a safe and appropriate V̇O 2max verification criterion in this population. [15] The primary outcome measure,
given its clinical important in CF, was V̇O 2max . However, additional submaximal parameters of aerobic fitness were also derived. The lactate threshold was noninvasively identified using the gas exchange threshold (GET) [18] and confirmed through visual inspection of the ventilatory equivalents for V̇O 2 and V̇CO 2 . The V̇O 2 "gain" (ΔV̇O 2 /ΔWR), a measure of exercise efficiency, was determined by regression of the "linear" portion of the V̇O 2 response against power output.
Additional mechanistic measures:
Thoracic bioelectrical impedance (PhysioFlow, PF-05, Manatec Biomedical, Paris, France), which has been validated in CF, [19] was used to noninvasively measure beat-by-beat heart rate (HR), stroke volume (SV) and cardiac output 
Arterial O 2 saturation at the fingertip (SpO 2 ) was measured on a beat-by-beat basis via pulse oximetry (NONIN, Avant 4000, NONIN Medical Inc., USA). Subjective ratings of perceived exertion (RPE) and dyspnea (RPD) were recorded upon exhaustion using methodology described elsewhere. [15, 16] All procedures and protocol were approved by the institutional ethics committee and informed parental consent and participant assent were obtained prior to the commencement of the study.
OUTCOMES
The 2 patients' clinical and exercise characteristics at baseline and in response to 12 weeks of treatment with ivacaftor are presented in Table 1 . Figure 2 presents the percentage change in BMI, FEV 1 and V̇O 2max during 12 weeks of treatment. BMI and FEV 1 were then monitored during follow-up up to week 20. The magnitude of change in these measurements is presented in relation to the established typical error of measurement using these procedures over a 4-6 week period 16 . All exercise testing was well tolerated with no adverse events, and all tests satisfied the criteria for the provision of a maximal effort. However, case B reported to his 12 week CPET feeling fatigued.
Case A
This patient experienced 2 successive upper respiratory tract infections (URTI) (weeks 3 and 10) during treatment. Despite this, her lung function and body weight were maintained when she would typically deteriorate. Following the first 6 weeks of treatment, her weight had increased from 48.5 kg to 50.5 kg, while predicted FEV 1 increased from 92% to 96%. A fall in her sweat chloride (104 to 21 mmol·L -1 ) was noted at this time point. Following 6 weeks of treatment her body mass normalized V̇O 2max had increased by 6.4% from baseline, which was not considered clinically a meaningful improvement since it resides within the typical error of this measurement 16 . End-exercise SpO 2 upon exhaustion increased from 92% to 96%.
Because of a combination of leg fatigue (9 out of 10) and dyspnea (rating of 7 out of 10)
CPET was terminated.
At the 12-week assessment, subjectively she reported feeling better and more "energetic" and was slightly more productive with airway clearance physiotherapy. Her FEV 1% and weight showed moderate though convincing increases (+4.7% relative and +1.7 kg, respectively). A small increase in sweat chloride (21 to 35 mmol·L -1 ) was evident.
Although there was minimal influence upon PPO, subjective ratings of exertion and dyspnea or the additional submaximal parameters of aerobic fitness (GET and V̇O 2 gain) at this time point, her body mass normalized V̇O 2max had increased by 30.3% from pretreatment baseline.
This substantial increase was deemed clinically meaningful since the change over this 6 week period exceeded the typical error (13.3%) of measurement established over this duration 16] .
Furthermore, end-exercise SpO 2 had improved to 98% from 95% pretreatment. By this point, her PPO had also increased by 9.0% (12 W) and her rating of dyspnea had improved from 7 to 5. Little change was detected in the submaximal parameters of aerobic fitness.
Of the factors which can affect patient A's V̇O 2max , a change was observed in both (Figure 2 ).
Her weight also increased further to 52.4 kg (+3.9 kg from baseline) at this stage.
Case B
This patient was clinically well throughout treatment and body weight and lung function remained stable. Following 6 weeks of treatment, his weight remained stable at 58.3 kg while lung function (FEV 1 ) improved from 108% to 112% predicted. A notable fall in sweat chloride (107 to 58 mmol·L -1 ) was also evident in this patient at this time point. A modest improvement in his body mass normalized V̇O 2max from baseline was evident (+3.4%);
however, this was not considered clinical meaningful. End-exercise SpO 2 was unchanged at 96% and CPET was terminated because of both leg fatigue (RPE of 9) and dyspnea (RPD of 7).
Following 12 weeks of treatment, he reported feeling clinically well; however he was tired because of heavy school and football workloads over the preceding weeks. In a patient who has difficulty maintaining weight, he had gained 0.5 kg by week 12. FEV 1 had also increased from 108% predicted at baseline to 120% predicted and sweat chloride concentration has reduced further to 43 mmol•L -1 . Although PPO increased by 9% from baseline (20 W) and SpO 2 at exhaustion had improved from 96% to 98%, his body mass normalized V̇O 2max was marginally reduced (-5.1% from baseline) as were the submaximal indicators of aerobic fitness. However, this should not be considered a true impairment of aerobic function as it is within the typical error of these measurements 16 . While his perceived dyspnea upon exhaustion was higher (7-9), RPE remained stable at 9. normalized to body mass was lower than case B at baseline, of which gender difference may be a factor. An impact of overreaching or chronic fatigue in case B also cannot be excluded.
Although a higher PPO was documented, this patient reported to the exercise laboratory for his week 12 CPET feeling tired, due to school and football workloads. His lower maximal heart rate (~20 beats·min -1 ) compared with his previous CPETs may support this.
Interestingly, this reduced response has previously been observed in this patient when he previously performed 2 CPETs over a short-term period. This stresses the importance of CPET standardization when interpreting "true" physiological changes in results. Although measures of O 2 delivery, extraction and minimum SpO 2 in this patient all fluctuated around baseline, without meaningful change, SV was elevated following 12 weeks. However, given that maximal HR was lower, his resulting ̇ was not increased.
To our knowledge, the only existing evidence of ivacaftor's effect upon aerobic fitness was demonstrated in a 19-year-old G551D homozygote with poor lung function using The data from this study are clinically useful for a number of reasons. Firstly, they are novel data regarding the mechanisms by which ivacaftor may enhance patients' physiological function during exercise. The magnitude of change in this patient was particularly impressive given that 1) she was in a state of URTI during the majority of her treatment, 2) improvements cannot simply be attributable to a learning effect or initial submaximal effort, because both patients were thoroughly familiarized with the protocol that encompasses a verification phase to confirm "true" V̇O 2max 15 ; and 3) no exercise training intervention was undertaken outside the patients' typical physical activity routine.
Sparse data exists concerning the magnitude of change in V̇O 2max of young patients with CF following pharmacological or exercise interventions. To date, only 1 previous study has demonstrated a meaningful improvement in V̇O 2max in young patients with CF and this was following an intense 6-week period of exercise training. Hulzebos et al. It is acknowledged that case study data are limited in its generalizability to the wider patient population. Furthermore, the follow-up time was relatively short and it would have been of interest to have performed CPET at week 20. In addition, no measurements of habitual physical activity were obtained to see whether improved exercise capacity translated into increased levels of physical activity.
Given the ongoing change in stance from the European Cystic Fibrosis Society regarding the clinical relevance of CPET in CF, it is likely that this will become a routine assessment method over the coming years. If more physical therapists involved in the management and treatment of this condition can adopt this form of testing, this would be of great benefit. It is hoped that this study demonstrates how insightful and relatively straightforward CPET is and will encourage more physical therapists to adopt it in clinical practice and as an investigative tool.
CONCLUSION
These cases demonstrate that not only does ivacaftor have a substantial beneficial effect on the sweat chloride of patients with CF and the G551D mutation, but clinically meaningful improvement in aerobic fitness can also be observed in the absence of exercise training.
These changes manifest earlier than current clinical outcomes and result from both improved muscle O 2 delivery and extraction during exercise. However, a fitness threshold may exist whereby patients who are relatively fit experience less or no improvement. Importantly, this case review highlights that CPET can provide an additional important clinical outcome measure to assess functional change and with this the mechanism(s) responsible for change.
CPET can detect substantial changes in aerobic fitness, which may occur independently from adaptations in pulmonary function, as was evidenced in 1 of the present patients. To objectively quantify the influence of pharmacological or physical therapy interventions on patients' physiological function, the use of CPET is encouraged. CPET should be included within future, long-term research demonstrating its utility within physical therapy practice, pharmacological or exercise interventions. 
